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Introduction
Major depression, human immunodeficiency virus (HIV) 
infection and acquired immunodeficiency syndrome (AIDS) 
contribute significantly to the global burden of disease, as 
indicated by the Global Burden of Disease study.1 This study 
showed that HIV/AIDS and major depressive disorders 
were the third and fourth most important causes of disease 
burden in 2002. The authors estimate that HIV/AIDS will be 
ranked first and depression second by 2030.1 
In Western countries, major depression has lifetime 
prevalence rates of around 15%.2 According to a meta-
analysis of 10 studies, this figure is nearly double in people 
living with HIV/AIDS (PLHIV).3 The estimated prevalence 
of major depression was 9.7% among the general 
population in South Africa in 2004.4 Few data are available 
on the prevalence of major depression and depressive 
disorders among PLHIV in the developing world. A study 
in Cape Town, South Africa, found the prevalence of major 
depression amongst PLHIV to be 14%,5 while research 
from Stellenbosch showed prevalence rates of 34% on 
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presentation and 26% at follow-up.6 These studies indicate 
a disparity in the prevalence of major depression, which 
could be related to the study population or to measurement 
tools. No prevalence data for major depression are available 
for PLHIV in KwaZulu-Natal, South Africa.
It is widely acknowledged that depressive disorders impact 
negatively on quality of life, mortality and adherence to 
medication among PLHIV.7-9 In addition, mental illness 
increases the possibility of engaging in risky behaviour such 
as unprotected intercourse.10
Literature specific to PLHIV with depression in developing 
countries is sparse, and little is known about clinical and 
socio-demographic factors associated with depression 
in this context.11 A Gambian study found that depressive 
symptoms were associated with a lack of income and a 
CD4 count of less than 200 cells/µl. In South Africa, among 
recently diagnosed PLHIV, depression was associated 
with female gender, disability and negative life events.12 
Depressive disorders among PLHIV were also thought to be 
related to the use of the antiretroviral drug efavirenz, but this 
was disputed by a large study in 2005.13
Optimal adherence to antiretroviral therapy (ART) is essential 
for viral suppression and positive treatment outcomes.14 
The negative impact of depressive disorders on adherence 
to ART has been demonstrated in developed countries.9 
There is evidence that the use of antidepressive medication 
leads to improved adherence.15 Few studies have explored 
whether there is an association between depression and 
adherence to ART in Africa and specifically South Africa. 
Research conducted in KwaZulu-Natal among PLHIV 
attending three public hospitals showed that depression 
significantly increased the risk of non-adherence.16 However, 
there is a lack of clinic-based data for South Africa despite 
the fact that the majority of people in this country access 
ART through clinic-based rather than hospital-based ART 
programmes. 
There are other factors, apart from depression, that may 
adversely affect adherence to ART among South Africans 
with HIV/AIDS. These include a low CD4 count at the onset 
of ART, a relatively poor understanding of the disease and 
a lack of social support.16 In addition, travelling costs, 
denial, waiting times at clinics, side effects of ART, use of 
traditional medicine, abuse of alcohol and being away from 
home have been identified as reasons for non-adherence in 
South Africa.17 
Globally, psychiatrists advocate increased integration of 
mental health services into HIV/AIDS care.18 
There is a paucity of local clinic-based data on depression 
and adherence to ART. The aim of this study was to explore 
whether there was any relationship between depressive 
symptoms and adherence to ART. The objectives of 
the study were (a) to screen for depression in a clinic-
based sample, (b) to determine demographic and clinical 
associations with depressive symptoms, (c) to determine 
demographic and clinical associations with non-adherence 
to ART and (d) to establish whether there was an association 
between depressive symptoms and nonadherence to ART. 
Method
Design and setting
This was a cross-sectional analytical study. The study was 
performed at a local government-funded ART clinic in a 
semi-urban isiZulu-speaking community on the outskirts of 
Durban, KwaZulu-Natal. About 1 420 patients are currently 
on ART at this clinic. Services provided at this clinic include 
counselling, nutritional assistance, psychosocial support 
and social welfare evaluation. 
Sample and procedure
The required sample size of 151 participants was 
determined by a biostatistician. The calculated sample size 
made provision for age, gender, level of education, source 
of income, length of time on ART and CD4 count to be 
considered as confounders.
A convenience sampling method was employed. To meet 
inclusion criteria, participants had to be 18 years and older, 
able to provide written informed consent, have been on ART 
for six months or more and due for routine blood tests on 
the day of the interview [CD4 count and viral load (VL) as per 
National Department of Health guidelines]. Clinic attendees 
who had been on treatment for less than six months were 
purposefully excluded in order to minimise the potential 
effect of concurrent illness or adjustment disorders on their 
measured depression scores. 
Questionnaires were translated into isiZulu by a qualified 
translator and back translated by counsellors from the clinic. 
A pilot study involving five clinic attendees was conducted 
to confirm that the isiZulu translation captured the meaning 
of the questionnaire.
Data were collected during a four-week period in October 
and November 2010. A trained and experienced isiZulu-
speaking research assistant invited all patients who 
were waiting to have routine blood samples taken to be 
interviewed in private. The response rate was excellent 
with all participants who were approached agreeing to 
participate. Signed informed consents for interviews and 
for data to be collected from files were obtained. Overall, 
160 interviews were conducted, of which 14 contained 
inadequate information or did not meet inclusion criteria. 
Therefore, 146 datasets were included in the analysis.
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Approval was obtained from the Biomedical Research Ethics 
Committee and the Postgraduate Committee at the Nelson 
R Mandela School of Medicine, University of KwaZulu-Natal 
and the KwaZulu-Natal Provincial Department of Health. 
Measuring instruments
Centre for Epidemiological Studies Depression Scale
The Centre for Epidemiological Studies Depression Scale 
(CES-D) was used to measure depressive symptoms. The 
CES-D has been translated into many languages and is used 
internationally in epidemiological studies and as a screening 
tool in clinical settings.19 It is a 20-item scale that assesses 
current levels of depression as defined by Diagnostic and 
Statistical Manual of Mental Disorders IV criteria. Scores on 
the CES-D range from 0 to 60 with scores of 16 or more 
accepted as indicative of major depression. Participants are 
asked to rate the frequency of symptoms as a response to 
statements such as “I felt lonely”, “I felt sad” and “I felt that 
my life had been a failure”. 
We chose to use the terms ”significant depressive 
symptoms” and ”CES-D-defined depression” for higher 
than threshold levels on the CES-D as no ideal brief 
measurement tool exists for major depression.19 Valenstein 
et al. documented that studies conducted since 1995 report 
high sensitivities (81–100%) and moderate specificities 
(51–88%) for various screening instruments.20 The CES-D 
has not been validated in the study population but has been 
validated in black undergraduate psychology students 
in South Africa.21 A recent study in Cape Town among 
Afrikaans- and Xhosa-speaking PLHIV found the CES-D 
to have a sensitivity of 79% [95% confidence interval (CI): 
76–83%] and a specificity of 61% (95% CI: 56–85%).5
The CES-D was chosen for this exploratory study because its 
wide use in epidemiological studies facilitates comparison 
among groups.22 The brevity of the questionnaire and 
the fact that it can be administered by a lay person are 
important advantages over more robust measures of 
depression such as structured clinical interviews.22 A further 
benefit in a setting where symptoms of depression and HIV-
related illness often overlap is that it places less emphasis 
on physical manifestations of depression compared to 
other instruments such as the Beck Depression Inventory.23 
The CES-D is reported to demonstrate very high internal 
consistency, adequate test-retest reliability and good 
discriminant validity.24
For this study, the CES-D had a satisfactory internal 
consistency (Cronbach’s alpha: 0.93). 
Pill counting
Pill counting was used as measure of adherence. Pill 
counting has been validated as a reliable, replicable and 
economical tool to assess adherence in resource-poor 
settings.25 Adherence is routinely assessed by pill counting 
at the clinic. Patients are required to bring all remaining 
tablets with them at follow-up visits. Tablets and number of 
days since last visit are counted and percentage adherence 
is calculated. The pill counting  recorded on the day of the 
interview was used as measure of adherence.
Demographic and clinical data
The questionnaire included demographic data on gender, 
age, level of education and source of income. The researcher 
obtained clinical data (length of time on ART, treatment 
regime, previous CD4 count and VL, and current CD4 count 
and VL) from patient charts. 
Data analysis
Data were analysed using Statistical Package for the Social 
SciencesTM version 18. Frequencies, means, standard 
deviations, median and inter-quartile range were calculated 
to describe the sample. Proportions and medians were 
compared using χ2 and Mann-Whitney U tests respectively. 
Variables were entered into a logistic regression model if 
they displayed appreciable association in bivariate analysis 
(p ≤ 0.1) or had theoretical importance. In the multivariate 
analysis, associations were considered significant at 
p ≤ 0.05. Backward stepwise regression was applied, using 
the likelihood ratio statistic to determine the removal of 
variables for the final model. In order to facilitate reporting, 
categories found to be significant in the regression model 
were further collapsed and retested for significance.
Results
A total of 146 datasets was analysed. The results are 
summarised in Table I. The median age of participants was 
36 years and the majority were female (62%).There were no 
reported differences in levels of education and employment 
status between male and female participants. Women 
were twice as likely to receive social grants compared to 
men (56% of women vs. 28% of men). Men were more 
likely than women to be dependent on family or friends for 
financial support (31% of men vs. 9% of women). Women 
had significantly higher median CD4 counts compared to 
men (346 cells/µl vs. 289cells/µl). The prevalence of CES-
D-defined depression was high (62%). A third of the sample 
(32%) was less than 95% adherent to ART in the month 
prior to the interview.
In bivariate analysis, level of education (not having 
progressed further than primary school) and source of 
income (dependency on social grants or on family and 
friends) were significantly associated with depressive 
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symptoms. Source of income (dependency on family and 
friends) and CD4 count were significantly associated with 
non-adherence to ART. 
Table II demonstrates significant associations with 
depressive symptoms in multivariate analysis. Unemployed 
participants were nearly three times more likely to be 
depressed [odds ratio (OR) 2.8; 95% CI, 1.3–6] than 
employed participants. Clinic attendees with primary school 
as highest level of education were twice more likely to score 
high on the depression scale than their more educated 
counterparts (OR 2; 95% CI, 1.0–4.1). There were no 
significant associations between depressive symptoms and 
clinical variables.
Unemployment was the only socio-demographic factor 
associated with non-adherence in multivariate analysis. 
Unemployed participants were twice more likely to be non-
adherent than employed participants (OR 2.4; 95% CI, 1.0–
6.1). The clinical variable associated with non-adherence 
was CD4 count. Participants with CD4 counts of 200– 
499 cells/µl were three times more likely to be non-adherent 
than those with higher or lower CD4 counts (OR 3; 95% CI, 
1.3–6.9). 
No significant association was found between CES-D-
defined depression and non-adherence to ART (OR 0.5; 
95% CI, 0.2–1.2; p=0.125).
Table I: Socio-demographic and clinical characteristics of the study sample (n = 146). P values are for the comparison between gender using χ2 
tests for proportions and Mann-Whitney U tests for medians.
Total Male Female P value
n = 146 n = 40 n = 106
Median age in years (aIQR) 36 (31–42) 38 (33–42) 35 (31–42) 0.110
Level of education n = 146 n = 40 n = 106
0.979
None 7 (5%) 2 (52%) 5 (5%)
Primary 75 (51%) 20 (50%) 55 (5%)
Higher and tertiary 64 (44%) 18 (45%) 46 (43%)
Source of income n = 146 n = 40 n = 106
0.002
Employed 51 (35%) 16 (40%) 35 (33%)
Grant 73 (50%) 12 (30%) 61 (58%)
Family 22 (15%) 12 (30%) 10 (9%)
bART n = 146 n = 40 n = 106
Median months on ART (IQR) 12 (6–25) 12 (6–19) 12 (6–25) 0.465
n = 145 n = 40 n = 105
Regimen with cEFV 116 (80%) 31 (78%) 85 (81%) 0.642
CD4 count (cells/µl) n = 138 n = 39 n = 99
0–199 37 (27%) 15 (39%) 22 (22%)
0.074
200–299 28 (20%) 7 (18%) 21 (21%)
300–399 23 (17%) 6 (15%) 17 (17%)
400–499 21 (15%) 8 (21%) 13 (13%)
500 + 29 (21%) 3 (8%) 26 (26%)
Median CD4 count (IQR) 312 (193–471) 289 (157–404) 346 (203–515) 0.039
Median change in CD4 from previous CD4 
result (IQR)
98 (24–189) 69 (15–160) 107 (37–197) 0.195
dVL (copies/ml ) n = 130 n = 36 n = 94
0.462
Detectable (≥ 40) 27 (21%) 9 (25%) 18 (19%)
Adherence n = 142 n = 39 n = 103
Non-adherent (< 95%) 45 (32%) 11 (28%) 34 (33%) 0.583
Depressive symptoms n = 146 n = 40 n = 106
 eCES-D score ≥ 16 
(on a scale 0-60)
91 (62%) 23 (58%) 68 (64%) 0.459
 Median CES-D score (IQR) 27 (6–41) 21 (4–38) 27 (6–42) 0.334
a= interquartile range; b= antiretroviral therapy; c= efavirenz; d= viral load 
e= Centres for Epidemiological Studies Depression Scale
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Table II: Results of a multivariate logistic regression on depressive 
symptoms and non-adherence
  P value aOR
95% bCI 
for OR
Associations with depressive symptoms (n = 145)
Education up to primary school 0.068 2.0 1.0–4.1
Unemployed 0.006 2.8 1.3–6.0
Associations with non-adherence (n = 133)
Symptoms of depression 0.125 0.5 0.2–1.2
Unemployed 0.063 2.4 1.0–6.1




The prevalence of depression varies greatly among different 
populations.11 This variability could be due to the use of 
different measures and methodologies or to differing study 
populations. The findings from this study are consistent with 
those of similar studies with the CES-D as measurement 
tool.26-28 In this study, 62% of participants scored high 
on the CES-D. The large percentage of participants with 
significant depressive symptoms suggests that there is 
a very high prevalence of major depression in this HIV-
positive population. 
This large proportion of participants with high depression 
scores may reflect a high burden of psychological distress 
linked to poverty. The findings from this study regarding the 
increased risk of significant depressive symptoms among 
the unemployed and among people with lower levels of 
education have been confirmed by studies from both 
middle- and low-income countries.29, 30 
It may be assumed that physically unwell PLHIV are likely 
to be more depressed than their healthy counterparts. 
However, a meta-analysis of 10 studies investigating 
the relationship between HIV infection and the risk for 
depressive disorders found that rates of depression were 
not linked to the disease stage of individuals with HIV.31 This 
study did not find a significant association between CD4 
count (as proxy of wellness) and depressive symptoms.
It is of concern that 32% of participants were less than 
95% adherent to ART. These adherence rates are similar 
to those of a study in KwaZulu-Natal using different 
measuring instruments.16 Unemployment has been linked 
to poor adherence to ART in this study and in another South 
African setting.32 These findings are not surprising as lack of 
finances is an enormous barrier to adherence in the African 
context.33 
The increased risk of non-adherence among participants 
with CD4 counts between 200 cells/µl and 499 cells/µl is 
noteworthy. It is plausible that our results reflect 
complacency towards adherence among participants with 
mid-range CD4 counts. Patients who are aware that they 
have very low CD4 counts (less than 200 cells/µl), however, 
may be more motivated to be adherent to ART. It stands 
to reason that good adherence results in high CD4 counts 
(over 500 cells/µl). A literature search rendered no current 
evidence supporting this suggestion.
It is of interest that there was no significant association 
between the relatively high prevalence of significant 
depressive symptoms and non-adherence to ART. It is 
possible that factors such as self-efficacy,34 the ability 
to express emotions,35 differing cultural expressions of 
psychological distress36 and complex adherence behaviour37 
influenced results. Another reason could be that few other 
studies exploring the risk of non-adherence in depressed 
patients have excluded participants who recently started 
ART. It has been shown in other populations that adherence 
improves over time38 while depression may persist.12 The 
likelihood that these phenomena were captured in our 
results needs to be considered in future research. 
This study has a number of limitations. First, the CES-D has 
not been validated in this population. In general, brief rating 
scales for depression lack specificity. Second, pill counting 
as measure of adherence is not without problems as it does 
not account for events such as the sharing or losing of 
tablets or patients throwing remaining tablets away in order 
to appear adherent. Third, the response rate was excellent, 
but the study sample may not have been representative of 
the study population as a convenience sampling method 
was employed. Fourth, all potential confounding factors, 
such as recent bereavement, alcoholism, major life events, 
social support, stigma and previous history of depression 
were not taken into account in the analysis. Fifth, the cross-
sectional design does not allow for conclusions to be drawn 
regarding temporal relationships between adherence and 
depressive symptoms. In light of the limitations, caution 
should be taken in generalising findings to other districts in 
South Africa.
Conclusion and recommendations
Research in Western contexts indicates a high prevalence of 
depression in PLHIV. It has also been shown that depressive 
disorders jeopardise the health outcomes of patients with 
HIV. Literature from the developing world on depression in 
PLHIV is limited. 
Brief rating scales for depression, though widely used, are not 
ideal diagnostic tools as they lack specificity. However, the 
large percentage of participants with significant depressive 
symptoms suggests that there is a high prevalence of major 
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depression in the study population. This study did not find a 
significant relationship between depressive symptoms and 
non-adherence to ART.
Participants with significant depressive symptoms were 
more likely to be unemployed and to have lower levels of 
education. Unemployed participants and those with mid-
range CD4 counts (200–499 cells/µl) were at increased risk 
of non-adherence to ART. Healthcare workers should be 
aware of the fact that these groups of patients are likely to 
require additional support.
Further studies using robust diagnostic tools are 
recommended to determine the prevalence, causes and 
impact of depression among PLHIV in South Africa and in 
the developing world.
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